Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.51 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205183 | 1.00 | CTSK (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL1487792 | 1.00 | CTSK (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL2191093 | 0.98 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL28031453 | 0.98 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL376450 | 0.95 | FOLH1 (0.53) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL47004 | 0.95 | FOLH1 (0.53) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL918952 | 0.95 | FOLH1 (0.53) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL30395713 | 0.94 | FOLH1 (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL28376761 | 0.94 | FOLH1 (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL6751878 | 0.94 | FOLH1 (0.51) | CTSKCTSSMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110563943-A | Bio-based polymer and preparation method thereof | 中国科学院长春应用化学研究所 | 2019-12-13 | — | — | CN | claimed |
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4634174-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025132943-A1 | DECAHYDROQUINOLINES AS DNA POLYMERASE THETA INHIBITORS | BREAKPOINT THERAPEUTICS GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024129600-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-117320759-A | Radiopharmaceutical somatostatin receptor ligands and precursors thereof | 慕尼黑工业大学 | 2023-12-29 | — | — | CN | disclosed |
| US-11795196-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-114057771-B | Macrocyclic compounds, their preparation and use | 北京鞍石生物科技有限责任公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-1228771-A | 1, 3-diheterocyclic metalloprotease inhibitors | PROCTER & GAMBLE (US) | 1999-09-15 | — | — | CN | disclosed |
| CN-1202161-A | Macrocyclic compounds as metalloproteinase inhibitors | DU PONT MERCK PHARMA (US) | 1998-12-16 | — | — | CN | disclosed |
| US-5710324-A | AMINE CONTAINING COMPOUNDS | MERRELL PHARMACEUTICALS INC. (US) | 1998-01-20 | — | — | US | disclosed |
| EP-0530537-B1 | Condensed pyrimidine derivatives, their production and use as antitumor agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-01-08 | — | — | EP | disclosed |
| US-5508432-A | TREATING GASTROINTESTINAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME INC. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5403843-A | Pyrrolopyrimidinyalglutaminate derivatives and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-04-04 | — | — | US | disclosed |
| US-5380872-A | Appetite suppresant, gall bladder disorders, CNS disorders | GLAXO INC. (US) | 1995-01-10 | — | — | US | disclosed |
| US-5318992-A | Administering for the treatment of hypotensive conditions and shock | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-06-07 | — | — | US | disclosed |
| EP-0530537-A1 | Condensed pyrimidine derivatives, their production and use as antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-10 | — | — | EP | disclosed |
| EP-0446699-A1 | Inhibitors of nitric oxide biosynthesis | MERRELL PHARMACEUTICALS INC. (US) | 1991-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | GNRHR, GHRHR, FSHR | CTSK 1751/4885CTSS 1316/4885MEN1 348/4885 |
| US-11795196-B2 | Mitochondria-targeting peptides | HSPE1, TFAM, TNNI3 | CTSK 909/4885CTSS 1818/4885MEN1 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.